Vertex Pharmaceuticals
Vertex Pharmaceuticals is a Boston-based biotech developing small-molecule and gene-editing therapies for serious diseases. It serves rare-disease patients globally through a dominant cystic fibrosis franchise (Trikafta/Alyftrek), the CRISPR-based Casgevy for sickle cell disease, and a growing pipeline spanning pain, kidney, and Type 1 diabetes.
- Company typePublic
- Founded1989
- HeadquartersBoston, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Vertex Pharmaceuticals does
Vertex Pharmaceuticals is a Boston-based, publicly traded (NASDAQ: VRTX) commercial-stage biotechnology company founded in 1989 and listed since 1991. It develops and commercializes small-molecule and gene-editing therapies for serious diseases, with a historical concentration in cystic fibrosis (CF) and an expanding portfolio that now spans sickle cell disease, transfusion-dependent beta thalassemia, acute pain, IgA nephropathy, APOL1-driven kidney disease, and Type 1 diabetes. The company serves rare-disease patients globally through a specialty distribution model, operating in 20+ countries with a workforce of approximately 5,000–6,500 employees.
Vertex's core technology centers on CFTR modulators — small molecules that restore function of the defective cystic fibrosis transmembrane conductance regulator protein — which underpin the Trikafta/Kaftrio franchise and the next-generation Alyftrek. Vertex has expanded into gene editing via Casgevy, a CRISPR-Cas9 ex vivo therapy co-developed with CRISPR Therapeutics for sickle cell disease and transfusion-dependent beta thalassemia, priced at approximately $2.2M per patient and delivered through a network of authorized treatment centers. Additional platforms include a non-opioid pain franchise (JOURNAVX/suzetrigine, approved by FDA in early 2025 as the first new mechanism of action for acute pain in over 20 years), the povetacicept BLA-stage asset (acquired through the $4.9B Alpine Immune Sciences deal, PDUFA November 30, 2026), zimislecel for Type 1 diabetes (acquired via the $320M ViaCyte deal in 2022), and inaxaplin for APOL1-driven kidney disease. Discovery is supported by DNA-encoded library screening, human genetics collaborations, and computational chemistry.
Vertex operates a direct-to-patient specialty pharmacy and authorized treatment center model for high-cost, complex therapies (CF franchise, Casgevy) and a more traditional launch infrastructure for JOURNAVX in acute pain. Revenue is generated principally from product sales of Trikafta/Alyftrek, which still represents the dominant share of total revenue, supplemented by Casgevy ramp, the recent JOURNAVX launch, and ex-US partnerships such as Zai Lab in China. FY2025 revenue was approximately $12B, with net income of approximately $4B (~33% margin), and management has guided 2026 revenue to $12.95–13.1B. The company executed $2.02B in share repurchases during 2025 alongside continued M&A and partnership activity.
Vertex Pharmaceuticals firmographics
Firmographics- Name
- Vertex Pharmaceuticals
- Legal name
- Vertex Pharmaceuticals Incorporated
- Website
- http://www.vrtx.com
- Company type
- Public
- Founded year
- 1989
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Vertex Pharmaceuticals is a Boston-based biotech developing small-molecule and gene-editing therapies for serious diseases. It serves rare-disease patients globally through a dominant cystic fibrosis franchise (Trikafta/Alyftrek), the CRISPR-based Casgevy for sickle cell disease, and a growing pipeline spanning pain, kidney, and Type 1 diabetes.
- Ownership category
- akta.pro rank
Vertex Pharmaceuticals industry classification
Industry- Product category
- Specialty Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
- akta.pro secondary industries
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Vertex Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices11 records
Markets served
Vertex Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Cystic Fibrosis Portfolio: Vertex's core revenue driver including Trikafta, Alyftrek, and other CFTR modulators. These are specialty pharmaceuticals sold to patients with cystic fibrosis through specialty pharmacies and direct distribution.
- Casgevy (Gene Therapy): CRISPR-based gene therapy for sickle cell disease and beta thalassemia, co-commercialized with CRISPR Therapeutics. One-time treatment priced at approximately $2.2 million per patient.
- Journavx (Pain Treatment): Non-opioid pain medication for moderate-to-severe acute pain. Generated approximately $90 million in first-year sales (2025).
- Povetacicept (if approved): If approved for IgA nephropathy, would be delivered as subcutaneous auto-injector every four weeks for chronic kidney disease treatment.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Trikafta/Kaftrio: ~$346,000/year in the US |
| One time/ perpetual license | Pay-as-you-go | Casgevy: ~$2.2 million per patient (one-time treatment) |
| Subscription | Monthly | Journavx: Below analyst expectations at ~$90M first-year sales |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
Vertex Pharmaceuticals product offering
Product offeringCore offering
Vertex Pharmaceuticals discovers, develops, and commercializes transformative medicines for serious diseases. Its portfolio centers on CFTR modulators for cystic fibrosis (Trikafta, Alyftrek), the CRISPR-Cas9 gene therapy Casgevy for sickle cell disease and transfusion-dependent beta thalassemia (co-developed with CRISPR Therapeutics), and the first oral non-opioid acute pain signal inhibitor JOURNAVX (suzetrigine). A growing pipeline includes povetacicept for IgA nephropathy, inaxaplin for APOL1-mediated kidney disease, and zimislecel, a stem cell-derived islet cell therapy for type 1 diabetes.
Product overview
Vertex Pharmaceuticals is a global biotechnology company focused on discovering, developing, and producing transformative medicines for serious diseases. The company operates a portfolio of approved medicines including Trikafta and Alyftrek for cystic fibrosis (its core franchise covering approximately 95% of CF patients), CASGEVY (the world's first CRISPR-based gene therapy for sickle cell disease and beta thalassemia, co-developed with CRISPR Therapeutics), and JOURNAVX (the first FDA-approved oral non-opioid pain signal inhibitor). Vertex's pipeline includes povetacicept for IgA nephropathy (with accepted BLA), inaxaplin for APOL1-mediated kidney disease, zimislecel for Type 1 diabetes, and additional programs in pain, Duchenne muscular dystrophy, and generalized myasthenia gravis. The company also developed Informed Pain Care, a telehealth platform for acute pain management.
Differentiator
Problem solved
Functional benefit
Products and services
- Trikafta (elexacaftor/tezacaftor/ivacaftor) A triple-combination CFTR modulator therapy for cystic fibrosis that targets the underlying cause of the disease by restoring CFTR protein function. Indicated for patients with at least one F508del mutation, representing the largest CF patient population.
- Alyftrek A next-generation CFTR modulator therapy for cystic fibrosis providing improved efficacy with once-daily dosing, expanding coverage to approximately 95% of CF patients in the United States.
- CASGEVY (exagamglogene autotemcel) The first FDA-approved CRISPR/Cas9-based gene therapy, administered at authorized treatment centers to edit a patient's own hematopoietic stem cells ex vivo to reactivate fetal hemoglobin production for the functional cure of severe sickle cell disease and transfusion-dependent beta thalassemia.
- JOURNAVX (suzetrigine) The first FDA-approved oral non-opioid selective NaV1.8 pain signal inhibitor for moderate-to-severe acute pain, providing pain relief without the addiction risks associated with opioid analgesics. Targets an estimated 80 million acute pain patients in North America and Europe.
- Povetacicept An engineered fusion protein dual inhibitor of BAFF and APRIL cytokines in development for IgA nephropathy and other B-cell mediated diseases, with FDA Breakthrough Therapy Designation. Phase 3 RAINIER trial showed 52% proteinuria reduction versus placebo. Planned delivery as a subcutaneous auto-injector every four weeks.
- Inaxaplin An investigational small molecule inhibitor targeting the APOL1 protein in development for APOL1-mediated kidney disease (AMKD), a progressive genetic kidney disorder.
- Zimislecel (VX-880) An allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy in development for Type 1 diabetes patients with impaired hypoglycemic awareness and severe hypoglycemia, designed to restore endogenous insulin production.
- Informed Pain Care A direct-to-patient telehealth platform developed with ixlayer for acute pain evaluation, connecting patients with licensed clinicians and providing access to non-opioid treatment options including JOURNAVX.
Quantifiable outcome
- 95% of US cystic fibrosis patients now eligible for Vertex CF treatments
- +4 more outcomes
Companies that use Vertex Pharmaceuticals
Customer profileNamed customers4 records
Segments6 records
Ideal customer profiles4 records
Vertex Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
Feature6 records
Vertex Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered minor and core.
- ixlayerminorCollaboration on Informed Pain Care telehealth platform for acute pain evaluation and access to non-opioid treatments including Journavx. Direct-to-patient healthcare expansion.
- Ono PharmaceuticalminorStrategic agreement announced in June 2025 for development of novel therapies.
- Orna TherapeuticsminorStrategic collaboration to develop next-generation approaches for sickle cell disease and transfusion-dependent beta thalassemia using Orna's technology.
- Zai LabminorStrategic agreement to develop and commercialize novel therapies.
- Alpine Immune SciencescoreAcquired Alpine Immune Sciences for $4.9 billion to obtain povetacicept, a pipeline-in-a-product asset for IgA nephropathy and other kidney diseases. Povetacicept received FDA Breakthrough Therapy Designation.
- CRISPR TherapeuticscoreLong-term partnership for co-development and commercialization of Casgevy (exagamglogene autotemcel), the world's first approved CRISPR-based gene therapy for sickle cell disease and beta thalassemia. Vertex leads commercialization with profits split 60/40 (Vertex 60%, CRISPR Therapeutics 40%).
- Entrada TherapeuticsminorCollaboration to discover and develop therapies for serious diseases using Entrada's endosomal escape platform.
- ViaCyteminorAcquired ViaCyte for $320 million in cash to accelerate stem cell-derived therapies for type 1 diabetes, including VX-880 (now zimislecel) and device encapsulation technology.
- Mammoth BiosciencesminorCollaboration to develop in vivo gene editing therapies using Mammoth's CRISPR systems.
- RibometrixminorStrategic collaboration to discover and develop small molecule medicines targeting RNA.
- ModernaminorCollaboration on inhaled mRNA therapies for cystic fibrosis (VX-522), though the program was discontinued in 2026 due to unresolved tolerability issues with lung inflammation from lipid nanoparticle delivery.
Scale indicators11 records
Recent moves6 records
Expansion highlights8 records
Vertex Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- BioMarin Pharmaceutical: Rare disease-focused biotechnology company with comparable revenue scale (~$2-3B) and similar strategy of developing transformative medicines for serious genetic conditions, including enzyme replacement therapies.
- CRISPR Therapeutics: Co-developer of Casgevy with Vertex (60/40 profit split). Direct strategic partner on the world's first approved CRISPR-based gene therapy for sickle cell disease and beta thalassemia, making it the most directly comparable peer for that product line.
- Biogen: Biotechnology company focused on neurological and rare diseases with similar specialty pharma commercial model. Comparable in therapeutic area focus and approach to serious disease drug development.
- Regeneron Pharmaceuticals: Innovative biotechnology company of similar size with blockbuster franchises (Eylea, Dupixent) treating serious diseases. Comparable in scale, R&D intensity, and focus on developing transformative medicines for high-unmet-need conditions.
- Alnylam Pharmaceuticals: RNA therapeutics pioneer developing innovative medicines for rare diseases. Highly comparable in platform innovation focus, specialty pharma commercial model, and treatment of serious genetic conditions.
- Moderna: mRNA therapeutics company that partnered with Vertex on VX-522 (CF program, discontinued 2026). Both companies are innovative biotechs pursuing platform-based therapeutic approaches for serious diseases.
Broad incumbents
- Novartis: Global pharmaceutical incumbent with first-approved CAR-T therapy (Kymriah) and gene therapy (Zolgensma). Major competitor in cell and gene therapy space with greater scale and resources.
- Pfizer: Global pharmaceutical leader with significant gene therapy investments and rare disease portfolio. Broad incumbent in serious disease therapeutics with multiple competing programs in non-opioid pain, sickle cell disease, and other Vertex focus areas.
- Bristol-Myers Squibb: Large pharmaceutical incumbent with established cell therapy franchises (Breyanzi, Abecma) and broad oncology/specialty portfolio. Provides competitive context as a larger player in cell and gene therapy.
- Gilead Sciences: Large biopharmaceutical company with cell therapy leadership (Yescarta, Tecartus) and virology expertise. Competes broadly in cell therapy and has significant commercial infrastructure advantages.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Vertex Pharmaceuticals social profiles
Digital presenceVertex Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vertex Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles12 records
Vertex Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries2 records
Vertex Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds8 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vertex Pharmaceuticals M&A and investment
M&A and investmentM&A9 records
Investments7 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vertex Pharmaceuticals
What does Vertex Pharmaceuticals do?
Vertex Pharmaceuticals discovers, develops, and commercializes transformative medicines for serious diseases. Its portfolio centers on CFTR modulators for cystic fibrosis (Trikafta, Alyftrek), the CRISPR-Cas9 gene therapy Casgevy for sickle cell disease and transfusion-dependent beta thalassemia (co-developed with CRISPR Therapeutics), and the first oral non-opioid acute pain signal inhibitor JOURNAVX (suzetrigine). A growing pipeline includes povetacicept for IgA nephropathy, inaxaplin for APOL1-mediated kidney disease, and zimislecel, a stem cell-derived islet cell therapy for type 1 diabetes.
Is Vertex Pharmaceuticals a public or private company?
Vertex Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Vertex Pharmaceuticals founded?
Vertex Pharmaceuticals was founded in 1989. It employs 5,001 to 10,000 people.
Where is Vertex Pharmaceuticals based?
Vertex Pharmaceuticals is headquartered in Boston, United States, in the North America region.
How does Vertex Pharmaceuticals make money?
Four revenue lines are on record. Cystic Fibrosis Portfolio is the primary driver. The others are casgevy (Gene Therapy), journavx (Pain Treatment) and povetacicept (if approved).
Who are Vertex Pharmaceuticals's main competitors?
Direct peers on record are BioMarin Pharmaceutical, CRISPR Therapeutics, Biogen, Regeneron Pharmaceuticals, Alnylam Pharmaceuticals and Moderna. Broad incumbents are Novartis, Pfizer, Bristol-Myers Squibb and Gilead Sciences.
Does Vertex Pharmaceuticals have an API?
No public API is recorded for Vertex Pharmaceuticals.
What industry is Vertex Pharmaceuticals in?
Vertex Pharmaceuticals's product category is Specialty Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2834.